CClinicalTrials.gg
Active, not recruitingNCT05521126Updated Jun 2, 2026

Micro-Doppler Radar: A Gold Standard Comparison

An observational study in Musculoskeletal Injury and Anterior Cruciate Ligament Injuries, sponsored by Milton S. Hershey Medical Center. Active, not recruiting at 2 sites in United States. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-02.

Sponsored by Milton S. Hershey Medical Center · Observational

Study type
Observational
Model
Case-control
Time perspective
Other
Enrollment
181
Ages
18 Years to 40 Years
Sex
All
01

Study summary

The purpose of this study is to see if the study team can use micro-Doppler signal (MDS) technology to determine if someone has had an anterior cruciate ligament (ACL) reconstruction. The investigators will do this by comparing the movement data from a group of people who have had the surgery with a group who has not had the surgery to see if the micro-Doppler radar technology can accurately and predictably tell the difference.

Read the detailed description

The objective of this research is to validate that radar MDS can accurately and predictably differentiate individuals at high-risk for MSKI from those who are low risk. The investigators hypothesize that MDS will identify individuals at a high-risk for MSKI more accurately than the gold-standard MC technologies. To test this hypothesis, the investigators propose a case control study that will compare adults who have undergone ACL reconstruction to a control group of healthy adults that has not. Patients who have undergone ACL reconstruction have a 6-24% chance of either re-tearing their ACL or having a subsequent knee surgery on either side within two years of successful completion of surgery and post-surgical rehabilitation. Despite being released for full activities, little is known about what makes this group at high-risk for re-tear. As such, the investigators will use this patient population as a model for identifying an at-risk population for musculoskeletal injury (MSKI). The researchers will simultaneously collect radar micro-Doppler signals and biomechanical motion capture (MC) data in a state-of-the-art human movement lab. Participants will be asked to perform a series of functional activities that will be captured by both the MDS radar and MC systems. The data sets will then be analyzed independently.

02

Conditions studied

  • Musculoskeletal Injury
  • Anterior Cruciate Ligament Injuries

Keywords

  • musculoskeletal injury
  • anterior cruciate ligament injury
  • anterior cruciate ligament repair
  • micro-Doppler radar
  • motion capture
03

In context

Anterior Cruciate Ligament Injuries

512 studies on the registry are indexed under Anterior Cruciate Ligament Injuries; 164 are open to participants now.

This study's enrollment of 181 is above the median of 92 across 127 observational studies indexed under Anterior Cruciate Ligament Injuries.

Browse Anterior Cruciate Ligament Injuries studies →

Lead sponsor

Milton S. Hershey Medical Center is the lead sponsor of 480 studies on the registry; 61 are open to participants now.

Of its 56 completed or terminated interventional studies of FDA-regulated products, 42 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

ACL repair cohort: Penn State Health Bone and Joint clinic

control cohort: Penn State University/College of Medicine students and employees, Lebanon Valley College students, community sample

Inclusion criteria

High risk cohort

  • age 18-40
  • history of ACL reconstruction
  • no current musculoskeletal injuries
  • ACL repair between 9 and 24 months prior to recruitment

Control cohort

  • age 18-40
  • never had lower extremity surgery

Exclusion criteria

Exclusion Criteria:

High risk cohort

  • age \<18 or >40
  • pregnancy
  • institutionalization
  • history of cerebral vascular accident
  • unable to provide informed consent
  • inability to perform study activities
  • history of hip or knee replacement
  • inability to walk or jump without a limp
  • current neuromuscular disease
  • any surgery in the last 6 months

Control cohort

  • age \< 18 or > 40
  • pregnancy
  • institutionalization
  • history of Cerebral Vascular Accident
  • unable to provide informed consent
  • inability to perform study activities
  • history of knee or hip replacement
  • inability to walk or jump without a limp
  • current neuromuscular disease
  • history of lower extremity surgery
  • any surgery in the last 6 months
05

Study design

Observational model
Case-control
Time perspective
Other
Enrollment
181 participants (actual)
Patient registry
No

Groups and cohorts

  • high risk/ACL repair cohort

    The high risk cohort will be subjects who have had an ACL reconstruction procedure 9-24 months prior to enrollment.

  • control group

    The control group will be individuals who have not had an ACL reconstruction procedure.

06

What researchers measure

Primary outcomes

  1. accuracy and predictability of MDS differentiation between ACL repair and control group

    The investigators hypothesize that MDS will differentiate subjects who have recovered from an ACL reconstruction from a control cohort with accuracy and predictability. Participants will perform drop jumps, sit to stand, and walk on a treadmill in the presence of the micro-Doppler radar. MDS will be obtained for the ACL group as well as control. The micro-Doppler signature projection algorithm (mD-SPA) will then be applied to the data sets showing what percentage of the MDS are successfully classified to the ACL group versus control.

    Time frame: Day 1

Secondary outcomes

  1. accuracy of MDS differentiation between ACL repair and control groups versus the motion capture system

    The investigators hypothesize that MDS will differentiate between the ACL group versus the control group with greater accuracy compared with the MC system. MDS will show greater sensitivity and specificity for correct classification compared with the gold standard MC. Participants will perform drop jumps, sit to stand, and walk on a treadmill while collecting simultaneously the motion capture data and MDS. The data sets will then be analyzed separately and the sensitivity and specificity of each system will be compared.

    Time frame: Day 1

  2. ability of micro-Doppler radar and deep learning algorithms to automatically produce predictive data

    The investigators hypothesize that by incorporating several deep learning algorithms that can extract high-level deep features automatically through hierarchical architectures, the system will be able to automatically produce predictive data that will not require specialized knowledge to operate. This will allow the system to be used by medical assistants or medical technicians who have no expertise in interpretation of the radar MDS. The investigators will accomplish this by applying numerous deep learning algorithms to the MDS to determine which algorithms most accurately and automatically classify the ACL group from control.

    Time frame: Day 1

07

Study locations

2 sites
  • Lebanon Valley College
    Annville, Pennsylvania 17003, United States
  • Pennsylvania State University College of Medicine
    Hershey, Pennsylvania 17033, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05521126
Lead sponsor
Milton S. Hershey Medical Center
Collaborators
United States Department of Defense, Lebanon Valley College
Responsible party
Cayce Onks (Associate Professor of Family Medicine and Orthopaedics, Milton S. Hershey Medical Center) — Principal investigator
First posted
Aug 30, 2022
Start date
Feb 21, 2023
Primary completion
Sep 1, 2025
Completion
Aug 2026 (estimated)
Last update
Jun 2, 2026

Study contacts

Cayce A Onks, DO, MS
principal investigator · Milton S. Hershey Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion